SLC3A2 and breast cancer: Here we implied that everolimus could regulate Th9 cells proliferation to affect BC cells viability when co-culture two kinds of cells, combination therapy to target FKBP1A/SLC3A2 axis should be considered to maximise the effectiveness of immunotherapy in this setting.